Curaxis Pharmaceutical Corporation: Press release

DURHAM, N.C., 2011-02-03 08:30 CET (GLOBE NEWSWIRE) --Patrick S. Smith, President and Chief Executive Officer of Curaxis
Pharmaceutical Corp (OTCBB:CURX), confirmed today that Curaxis Management will
be in Europe for the first part of February. Curaxis has been approved to trade
on the Frankfurt stock exchange ("FSE") under the symbol 8CX to expand its
global capital markets access. Along with its U.S. investment bankers, Curaxis
has engaged a European Advisor, Continental Advisors, to complement its
European capital markets initiatives as well as explore further business
development or European strategic partnerships. 

Mr. Smith stated, "More than 3,000 U.S. companies have chosen a FSE listing.
The FSE's trading volume grew by a staggering 39% when comparing December 2009
to December 2010. The liquidity of stocks listed on the FSE is the highest in
all of Europe, including the London and Paris Stock Exchanges. In fact, market
liquidity and trading volume on the FSE is third in the entire world, behind
only the NASDAQ and NYSE."   Furthermore, naked short selling was completely
banned in Germany in June of 2010. 

The FSE has more than 250 international trading institutions and more than
4,500 traders worldwide. Investors directly connected to the FSE represent a
full 35% of the world's investment capital. 

About Curaxis

Curaxis is an emerging specialty pharmaceutical company with a hormone drug
product candidate for the treatment of Alzheimer's disease and multiple
cancers.  Curaxis' therapeutic platform is based on the hypothesis that many
diseases of aging may be caused by age-related changes in the function of the
hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine
feedback loop that controls development, reproduction and aging in animals. 
This drug development platform is built on the premise that hormones associated
with this feedback loop are beneficial early in life, when they promote growth
and development, but are harmful later in life when the mechanism for feedback
is compromised, thereby leading to disease processes, including pathologies
associated with Alzheimer's disease and various cancers. 

Notice Regarding Forward Looking Statements

This press release includes certain "Forward-Looking Statements" within the
meaning of section 21E of the Securities Exchange Act of 1934, as amended. All
statements regarding potential results and future plans and objectives of
Curaxis Pharmaceutical Corporation are forward-looking statements that involve
various risks and uncertainties. There can be no assurance that such statements
will prove to be accurate and actual results and future events could differ
materially from those anticipated in such statements. Important factors that
could cause actual results to differ materially from our expectations include,
but are not limited to, those factors that are disclosed under the heading
"Risk Factors" and elsewhere in our documents filed from time to time with the
Securities and Exchange Commission. Other risk factors may include, but are not
limited to, fluctuation in quarterly results, and increased competition in our
operations, our ability to continue operations as scheduled, and our ability to
protect the proprietary technology we use. Further, the company operates in an
industry sector where securities values are highly volatile and may be
influenced by economic and other factors beyond the company's control, such as
announcements by competitors and service providers. 

The contents of this press release are presented as a general overview of the
company. It is intended only to contain general information regarding the
company and its business and does not purport to provide complete disclosure or
analysis of all matters, which may be relevant to a decision to make an
investment, including all risk factors or similar considerations. Although the
information is believed current as of the date herein, the information may be
subject to change, amendment or supplementation, and the company does not
expect, and assumes no obligation, to update or otherwise revise the
information herein. 

         CONTACT: Curaxis Pharmaceutical Corp
         Company Contact: David Corcoran
         Email: dcorcoran@curaxispharma.com
         
         European Advisor: Andreea Porcelli
         Phone: 0035-2-2088-0289
         Email: andreea.porcelli@contiadvisors.com